{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:46:59Z","timestamp":1771019219195,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH-2-R01-CA238429-01"],"award-info":[{"award-number":["NIH-2-R01-CA238429-01"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bispecific T cell engaging antibodies (bsAbs) have emerged as novel and powerful therapeutic agents for redirecting T cells towards antigen-specific tumor killing. The cell surface glycoprotein and SLAM family member, CS1, exhibits stable and high-level expression on malignant plasma cells including multiple myeloma, which is indicative of an ideal target for bsAb therapy. Here, we developed a CS1 bsAb (CS1-dbBiTE) using Click chemistry to conjugate intact anti-CS1 antibody (Elotuzumab) and anti-huOKT3 antibody at their respective hinge regions. Using a cellular therapy approach, human T cells were armed ex-vivo with CS1-dbBiTE prior to examining effector activity. Our data indicates that arming T cells with CS1-dbBiTE induced T cell activation and expansion and subsequent cytotoxic activity against CS1-bearing MM tumors, demonstrated by significant CD107a expression as well as inflammatory cytokine secretion. As expected, CS1-dbBiTE armed T cells showed significantly reduced effector activity in the absence of CS1 expression. Similarly, in MM mouse xenograft studies, armed T cells exhibited effective anti-tumor efficacy highlighted by reduced tumor burden in MM.1S tumor-bearing mice compared to controls. On the basis of these findings, the rationale for CS1 targeting by human T cells armed with CS1-dbBiTE presents a potentially effective therapeutic approach for targeting MM.<\/jats:p>","DOI":"10.1038\/s41598-023-47115-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T20:02:28Z","timestamp":1701115348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Dennis","family":"Awuah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Urak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Kujawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Shively","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"47115_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"47115_CR2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.Mct-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama, T. et al. Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 1555\u20131564. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-1216 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"47115_CR3","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805 (2021).","journal-title":"Blood Adv."},{"key":"47115_CR4","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/jco.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg, A. et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381\u20134389. https:\/\/doi.org\/10.1200\/jco.2016.67.3301 (2016).","journal-title":"J. Clin. Oncol."},{"key":"47115_CR5","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.Ccr-18-2752","volume":"25","author":"CL ZuchdeZafra","year":"2019","unstructured":"ZuchdeZafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921\u20133933. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2752 (2019).","journal-title":"Clin. Cancer Res."},{"key":"47115_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today 20, 838\u2013847. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008 (2015).","journal-title":"Drug Discov. Today"},{"key":"47115_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","volume":"182","author":"Z Wu","year":"2018","unstructured":"Wu, Z. & Cheung, N. V. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacol. Ther. 182, 161\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.005 (2018).","journal-title":"Pharmacol. Ther."},{"key":"47115_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","volume":"5","author":"M Subklewe","year":"2021","unstructured":"Subklewe, M. BiTEs better than CAR T cells. Blood Adv. 5, 607\u2013612. https:\/\/doi.org\/10.1182\/bloodadvances.2020001792 (2021).","journal-title":"Blood Adv."},{"key":"47115_CR9","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","volume":"98","author":"R Wong","year":"2013","unstructured":"Wong, R. et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 98, 1930\u20131938. https:\/\/doi.org\/10.3324\/haematol.2012.082248 (2013).","journal-title":"Haematologica"},{"key":"47115_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917\u2013927. https:\/\/doi.org\/10.1038\/leu.2013.279 (2014).","journal-title":"Leukemia"},{"key":"47115_CR11","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.Ccr-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi, E. D. et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14, 2775\u20132784. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-4246 (2008).","journal-title":"Clin. Cancer Res."},{"key":"47115_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcyt.2017.03.077","volume":"19","author":"M Rosenzweig","year":"2017","unstructured":"Rosenzweig, M. et al. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy 19, 861\u2013866. https:\/\/doi.org\/10.1016\/j.jcyt.2017.03.077 (2017).","journal-title":"Cytotherapy"},{"key":"47115_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai, Y. T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329\u20131337. https:\/\/doi.org\/10.1182\/blood-2007-08-107292 (2008).","journal-title":"Blood"},{"key":"47115_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos, M. A. et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 10, 91. https:\/\/doi.org\/10.1038\/s41408-020-00357-4 (2020).","journal-title":"Blood Cancer J."},{"key":"47115_CR15","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/s2352-3026(15)00197-0","volume":"2","author":"PG Richardson","year":"2015","unstructured":"Richardson, P. G. et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: Final phase 2 results from the randomised, open-label, phase 1b\u20132 dose-escalation study. Lancet Haematol. 2, e516-527. https:\/\/doi.org\/10.1016\/s2352-3026(15)00197-0 (2015).","journal-title":"Lancet Haematol."},{"key":"47115_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin. Cancer Res. 24, 106\u2013119. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0344 (2018).","journal-title":"Clin. Cancer Res."},{"key":"47115_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700. https:\/\/doi.org\/10.1182\/blood-2016-04-711903 (2016).","journal-title":"Blood"},{"key":"47115_CR18","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280. https:\/\/doi.org\/10.1200\/JCO.2018.77.8084 (2018).","journal-title":"J. Clin. Oncol."},{"key":"47115_CR19","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226 (2019).","journal-title":"N. Engl. J. Med."},{"key":"47115_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","volume":"11","author":"C Caraccio","year":"2020","unstructured":"Caraccio, C., Krishna, S., Phillips, D. J. & Sch\u00fcrch, C. M. Bispecific antibodies for multiple myeloma: A review of targets, drugs, clinical trials, and future directions. Front. Immunol. 11, 501\u2013501. https:\/\/doi.org\/10.3389\/fimmu.2020.00501 (2020).","journal-title":"Front. Immunol."},{"key":"47115_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3389\/fonc.2020.00544","volume":"10","author":"LG Lum","year":"2020","unstructured":"Lum, L. G. et al. Anti-CS1 \u00d7 anti-CD3 bispecific antibody (BiAb)-armed anti-CD3 activated T cells (CS1-BATs) kill CS1+ myeloma cells and release type-1 cytokines. Front. Oncol. 10, 544. https:\/\/doi.org\/10.3389\/fonc.2020.00544 (2020).","journal-title":"Front. Oncol."},{"key":"47115_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s12885-019-6056-8","volume":"19","author":"M Kujawski","year":"2019","unstructured":"Kujawski, M. et al. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy. BMC Cancer 19, 882\u2013882. https:\/\/doi.org\/10.1186\/s12885-019-6056-8 (2019).","journal-title":"BMC Cancer"},{"key":"47115_CR23","doi-asserted-by":"publisher","first-page":"7675","DOI":"10.1073\/pnas.0402295101","volume":"101","author":"L Kjer-Nielsen","year":"2004","unstructured":"Kjer-Nielsen, L. et al. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc. Natl. Acad. Sci. USA 101, 7675\u20137680. https:\/\/doi.org\/10.1073\/pnas.0402295101 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"47115_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974. https:\/\/doi.org\/10.1126\/science.1158545 (2008).","journal-title":"Science"},{"key":"47115_CR25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"SM Collins","year":"2013","unstructured":"Collins, S. M. et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC. Cancer Immunol. Immunother. 62, 1841\u20131849. https:\/\/doi.org\/10.1007\/s00262-013-1493-8 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"47115_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373, 621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654 (2015).","journal-title":"N. Engl. J. Med."},{"key":"47115_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cts.12532","volume":"11","author":"D Ritchie","year":"2018","unstructured":"Ritchie, D. & Colonna, M. Mechanisms of action and clinical development of elotuzumab. Clin. Transl. Sci. 11, 261\u2013266. https:\/\/doi.org\/10.1111\/cts.12532 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"47115_CR28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379, 1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1805762 (2018).","journal-title":"N. Engl. J. Med."},{"key":"47115_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2021-147323","volume":"138","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt, H. et al. Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: Results from the randomized phase III GMMG-HD6 Trial. Blood 138, 486\u2013486. https:\/\/doi.org\/10.1182\/blood-2021-147323 (2021).","journal-title":"Blood"},{"key":"47115_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","volume":"154","author":"D Ellerman","year":"2019","unstructured":"Ellerman, D. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods 154, 102\u2013117. https:\/\/doi.org\/10.1016\/j.ymeth.2018.10.026 (2019).","journal-title":"Methods"},{"key":"47115_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120760","volume":"271","author":"S Jang","year":"2021","unstructured":"Jang, S. et al. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy. Biomaterials 271, 120760. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120760 (2021).","journal-title":"Biomaterials"},{"key":"47115_CR32","doi-asserted-by":"publisher","first-page":"e000222","DOI":"10.1136\/jitc-2020-002222","volume":"9","author":"JA Park","year":"2021","unstructured":"Park, J. A., Santich, B. H., Xu, H., Lum, L. G. & Cheung, N. V. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J. Immunother. Cancer 9, e000222. https:\/\/doi.org\/10.1136\/jitc-2020-002222 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"47115_CR33","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018\u20131028. https:\/\/doi.org\/10.1056\/NEJMoa063842 (2006).","journal-title":"N. Engl. J. Med."},{"key":"47115_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/bmt.2013.133","volume":"49","author":"LG Lum","year":"2014","unstructured":"Lum, L. G. et al. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin\u2019s lymphoma: A pilot study. Bone Marrow Transplant. 49, 73\u201379. https:\/\/doi.org\/10.1038\/bmt.2013.133 (2014).","journal-title":"Bone Marrow Transplant."},{"key":"47115_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/285193","volume":"2015","author":"U Vaishampayan","year":"2015","unstructured":"Vaishampayan, U., Thakur, A., Rathore, R., Kouttab, N. & Lum, L. G. Phase I study of anti-CD3 x anti-Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate Cancer 2015, 285193. https:\/\/doi.org\/10.1155\/2015\/285193 (2015).","journal-title":"Prostate Cancer"},{"key":"47115_CR36","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo, D. J. et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 5, 1291\u20131304. https:\/\/doi.org\/10.1182\/bloodadvances.2020002736 (2021).","journal-title":"Blood Adv."},{"key":"47115_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","volume":"7","author":"C Graham","year":"2018","unstructured":"Graham, C., Jozwik, A., Pepper, A. & Benjamin, R. Allogeneic CAR-T cells: More than ease of access?. Cells 7, 155. https:\/\/doi.org\/10.3390\/cells7100155 (2018).","journal-title":"Cells"},{"key":"47115_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","volume":"30","author":"K Brischwein","year":"2007","unstructured":"Brischwein, K. et al. Strictly target cell-dependent activation of T Cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 30, 798\u2013807 (2007).","journal-title":"J. Immunother."},{"key":"47115_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.Cd-18-0297","volume":"8","author":"CY Slaney","year":"2018","unstructured":"Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: A comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 8, 924\u2013934. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0297 (2018).","journal-title":"Cancer Discov."},{"key":"47115_CR40","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.Ccr-16-1860","volume":"23","author":"CY Slaney","year":"2017","unstructured":"Slaney, C. Y. et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res. 23, 2478\u20132490. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1860 (2017).","journal-title":"Clin. Cancer Res."},{"key":"47115_CR41","doi-asserted-by":"publisher","first-page":"57964","DOI":"10.18632\/oncotarget.19865","volume":"8","author":"LA Horn","year":"2017","unstructured":"Horn, L. A. et al. CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget 8, 57964\u201357980. https:\/\/doi.org\/10.18632\/oncotarget.19865 (2017).","journal-title":"Oncotarget"},{"key":"47115_CR42","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp, S. et al. A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31, 1743\u20131751. https:\/\/doi.org\/10.1038\/leu.2016.388 (2017).","journal-title":"Leukemia"},{"key":"47115_CR43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah, E. et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283. https:\/\/doi.org\/10.1038\/s41467-020-16160-5 (2020).","journal-title":"Nat. Commun."},{"key":"47115_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","volume":"5","author":"R Urak","year":"2017","unstructured":"Urak, R. et al. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J. Immunother. Cancer 5, 26\u201326. https:\/\/doi.org\/10.1186\/s40425-017-0227-4 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"47115_CR45","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263. https:\/\/doi.org\/10.1182\/blood-2011-02-337360 (2011).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47115-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T20:05:58Z","timestamp":1701115558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47115-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47115"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47115-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20853"}}